June 13, 2003Open Access

Results of decitabine (5‐aza‐2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Decitabine appears to have significant anti-CML activity. Future studies should evaluate lower-dose, longer-exposure decitabine schedules alone in imatinib-resistant CML, as well as combinations of decitabine and imatinib in different CML phases.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Kantarjian et al. (Fri,) studied this question.

synapsesocial.com/papers/69ecef1dd55980bedc8fe5be https://doi.org/https://doi.org/10.1002/cncr.11543

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Chronic myelogenous leukemia in blast crisis1987 · 281 citations
2Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin2001 · 66 citations
3Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results.1993 · 84 citations
4A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).1997 · 88 citations
5DNA methylation changes in hematologic malignancies: biologic and clinical implications.1997 · 153 citations

Me gusta

Guardar

Ver artículo completo